Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Regulatory Admin

Canadian Investment Regulatory Organization Trading Halt - RVV

By The Northwire Desk — AI Analysis Jun 08, 2026 · 08:04 RVV · 0.03 Revive Therapeutics Ltd.
RVV · Price

Executive Summary

  • The Canadian Investment Regulatory Organization (CIRO) has imposed a trading halt on Revive Therapeutics Ltd. (CSE: RVV) effective June 8, 2026, at 7:49 AM ET.
  • The halt is being executed due to a Cease Trade Order to ensure a fair and orderly market.
  • CIRO has stated that no additional information regarding the specific halt will be provided beyond the official notice.

Key Details

  • Company: Revive Therapeutics Ltd.
  • CSE Symbol: RVV
  • Halt Reason: Cease Trade Order
  • Halt Time (ET): 7:49 AM on June 8, 2026
  • Regulatory Authority: Canadian Investment Regulatory Organization (CIRO)
  • Policy Note: CIRO staff cannot provide further details about the halt beyond the published notice. General inquiries must be directed to CIRO's Complaints & Inquiries team or the company directly.
Read the original news release →

More from Revive Therapeutics Ltd.

Jun 26, 2026 · 16:15

Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.

Financings May 20, 2026 · 07:45

Revive Therapeutics Patents Fuel Defense Strategy Amidst Price Consolidation

M&A / Property Mar 11, 2026 · 17:34

Revive Therapeutics advances bucillamine patents

M&A / Property Mar 11, 2026 · 07:30

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

M&A / Property Feb 27, 2026 · 18:58

SEDAR Interim Financial Statements

None Dec 15, 2025 · 17:09

Revive Therapeutics primes the pump on Bucillamine

Other